Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 278

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 278
---
 reimbursement of expenditures incurred. During the three months ended September 30, 2024, the Company received $ 236 (2023 - $ 13)for grants received against research and development expenditures in the period. The grant is subject to various performance conditions and funding risk where the financial conditions of the NIH may change from time to time. The Company recognizes the grant only to the extent there is reasonable assurance the grant will be funded to the Company.

5 Property and equipment, net

| Balance, June 30, 2024      |     | $(thousands) | 674 |   |
|:----------------------------|:----|:-------------|----:|:--|
| Depreciation                |     |              | (17 | ) |
| Balance, September 30, 2024 |     |              | 657 |   |

<div align='center'>F-3 9</div>

At September 30, 2024, the total capitalized cost of property and equipment was $ 879(June 30, 2024 - $ 879),of which $ 499is not in use. The Company has recognized $ 17(2023 - $ 15) in depreciation expense in the three months ended September 30, 2024, on equipment in use.

6 Accounts payable and accrued liabilities

|                     |     | September 30,2024$(in thousands) |       |     | June 30,2024$(in thousands) |       |
| Trade payables      |     |                                  | 1,871 |     |                             | 1,464 |
| Accrued liabilities |     |                                  |   336 |     |                             |   743 |
| Balance             |     |                                  | 2,207 |     |                             | 2,207 |

7 Related party transactions Valent Technologies, LLC Agreements On November 20, 2023, Dr. Brown was terminated from his position as the Company’s Chief Scientific Officer as a result of cost-cutting measures adopted by the Company; he remains a consultant to the Company. Dr. Brown is a principal of Valent Technologies, LLC (“Valent”) and as a result Valent is a related party to the Company. On September 12, 2010, the Company entered into a Patent Assignment Agreement (the “Valent Assignment Agreement”) with Valent pursuant to which Valent transferred to the Company all its right, title and interest in, and to, the patents for VAL-083owned by